Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MICHAEL S ABRAMS Insider Profile
4 Followers
MICHAEL S ABRAMS, CFO at Arch Therapeutics, holds 10.29K shares in Arch Therapeutics (Ticker: ARTH). Most recently, MICHAEL S ABRAMS Bought $10,292 shares of Arch Therapeutics on Sep 08, 2023 for an estimated value of 2.78K.
MICHAEL S ABRAMS has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of MICHAEL S ABRAMS's holdings
Insider Roles
CFO
Roles that MICHAEL S ABRAMS holds in companies
Most Profitable Insider Trade
The most profitable trade made by MICHAEL S ABRAMS
MICHAEL S ABRAMS's Trading History
List of latest transactions for each holding click on a transaction to see MICHAEL S ABRAMS's performance on stock
You May Also Like
MICHAEL S ABRAMS insider profile FAQ
What is the percentage of profitable transactions made by MICHAEL S ABRAMS?
The percentage of profitable transactions made by MICHAEL S ABRAMS is ―.
What is the average return per transaction made by MICHAEL S ABRAMS?
The average return per transaction made by MICHAEL S ABRAMS is ―.
What stocks does MICHAEL S ABRAMS hold?
MICHAEL S ABRAMS holds: ARTH stocks.
What was MICHAEL S ABRAMS’s latest transaction?
MICHAEL S ABRAMS latest transaction was an Informative Buy of $2.78K.
What was MICHAEL S ABRAMS's most profitable transaction?
MICHAEL S ABRAMS’s most profitable transaction was an Informative Buy of ARTH stock on September 8, 2023. The return on the trade was 57.60%.
What is MICHAEL S ABRAMS's role in Arch Therapeutics?
MICHAEL S ABRAMS's role in Arch Therapeutics is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.